News

Novavax swings to profit, says talks with FDA on COVID vaccine approval ongoing
Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...
Novavax rises after massive Q1 beat, guidance raise
Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...
Novavax swings to profit on lower expenses related to COVID shots
Novavax on Thursday swung to a first-quarter profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines, its only product on the market.
FDA may ask Novavax to conduct additional trials of its Covid-19 vaccine to receive full approval
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots
The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine — the nation's only traditional ...
RFK Jr. takes aim at COVID shots for kids, worrying vaccine experts
Momentum is building to scale back the current recommendation that all children over 6 months old get immunized against the ...
BioPharma Dive9d
Novavax says vaccine application still ‘approvable,’ despite FDA delay
Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...
FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...
COVID vaccine boosters called into question by FDA chief: ‘Void of data’
Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...
IFLScience on MSN22h
A blanket requirement for placebo-controlled trials threatens research ethics and vaccine access, it’s being argued.
A blanket requirement for placebo-controlled trials threatens research ethics and vaccine access, it’s being argued.
Novavax: Q1 Earnings Snapshot
(NVAX) on Thursday reported first-quarter profit of $518.6 million. On a per-share basis, the Gaithersburg, Maryland-based company ...
The Daily Record (Maryland)7d
FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots
The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional protein-based option for the coronavirus — is sowing ...